Analyst Price Target is $33.50
▲ +135.58% Upside Potential
This price target is based on 3 analysts offering 12 month price targets for Vera Therapeutics in the last 3 months. The average price target is $33.50, with a high forecast of $0.00 and a low forecast of $0.00. The average price target represents a 135.58% upside from the last price of $14.22.
Current Consensus is
The current consensus among 3 investment analysts is to buy stock in Vera Therapeutics.
Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases in the United States. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase IIb clinical trial for patients with immunoglobulin A nephropathy. It is also developing MAU868, a monoclonal antibody for the treatment of BK viremia infections and is under Phase 2 clinical trial. The company was formerly known as Trucode Gene Repair, Inc. and changed its name to Vera Therapeutics, Inc. in April 2020. Vera Therapeutics, Inc. was incorporated in 2016 and is headquartered in Brisbane, California.